SCHEMBL19631763

SCHEMBL19631763

COc1ccc(CN(c2ncns2)S(=O)(=O)c2ccc(N)c(Cl)c2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.46
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.35
ALDH1A1 P00352 2/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
KCNH2 Q12809 1/20 0.34
POLB P06746 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
DHFR P00374 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 2/20 0.33
TSHR P16473 2/20 0.33
CYP2C19 P33261 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1095344 0.89 SCN9A (0.46) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL29669273 0.89 SCN9A (0.46) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL20449150 0.89 SCN9A (0.46) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL20449236 0.88 SCN9A (0.46) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL20449132 0.88 SCN9A (0.45) SCN9ATP53MAPTPOLBNPC1
SCHEMBL28671883 0.87 SCN9A (0.44) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL31093262 0.86 SCN9A (0.43) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL22088317 0.86 SCN9A (0.43) SCN9ATP53MAPTALDH1A1HTR2A
SCHEMBL20449131 0.86 SCN9A (0.44) SCN9ATP53MAPTALDH1A1POLB
SCHEMBL28526642 0.86 SCN9A (0.48) SCN9ATP53ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN9A 52/4885TP53 1139/4885MAPT 145/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN9A 52/4885TP53 1139/4885MAPT 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.